295 related articles for article (PubMed ID: 15535426)
21. FGF21: a novel prospect for the treatment of metabolic diseases.
Kharitonenkov A; Shanafelt AB
Curr Opin Investig Drugs; 2009 Apr; 10(4):359-64. PubMed ID: 19337957
[TBL] [Abstract][Full Text] [Related]
22. Novel therapeutic targets for appetite regulation.
Small CJ; Parkinson JR; Bloom SR
Curr Opin Investig Drugs; 2005 Apr; 6(4):369-72. PubMed ID: 15898343
[TBL] [Abstract][Full Text] [Related]
23. [Pharmaco-proteomic analysis: application of proteomic analysis to the discovery and development of new drugs].
Chapal N; Laplanche M; Ribes G; Pau B; Garin J; Petit P
J Soc Biol; 2002; 196(4):317-22. PubMed ID: 12645303
[TBL] [Abstract][Full Text] [Related]
24. Antidiabetic medications in overweight/obese patients with type 2 diabetes: drawbacks of current drugs and potential advantages of incretin-based treatment on body weight.
Bonora E
Int J Clin Pract Suppl; 2007 Aug; (154):19-28. PubMed ID: 17593274
[TBL] [Abstract][Full Text] [Related]
25. Ligand screening system using fusion proteins of G protein-coupled receptors with G protein alpha subunits.
Suga H; Haga T
Neurochem Int; 2007; 51(2-4):140-64. PubMed ID: 17659814
[TBL] [Abstract][Full Text] [Related]
26. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
Bharate SB; Nemmani KV; Vishwakarma RA
Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
[TBL] [Abstract][Full Text] [Related]
27. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight.
Pi-Sunyer FX
Postgrad Med; 2008 Jul; 120(2):5-17. PubMed ID: 18654064
[TBL] [Abstract][Full Text] [Related]
28. Orphan GPCRs and their ligands.
Civelli O; Saito Y; Wang Z; Nothacker HP; Reinscheid RK
Pharmacol Ther; 2006 Jun; 110(3):525-32. PubMed ID: 16289308
[TBL] [Abstract][Full Text] [Related]
29. Orphan G protein-coupled receptors: from DNA to drug targets.
Shaaban S; Benton B
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):535-47. PubMed ID: 12825450
[TBL] [Abstract][Full Text] [Related]
30. Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders.
Heal DJ; Smith SL; Fisas A; Codony X; Buschmann H
Pharmacol Ther; 2008 Feb; 117(2):207-31. PubMed ID: 18068807
[TBL] [Abstract][Full Text] [Related]
31. New insights into GPCR function: implications for HTS.
Eglen RM; Reisine T
Methods Mol Biol; 2009; 552():1-13. PubMed ID: 19513638
[TBL] [Abstract][Full Text] [Related]
32. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
[TBL] [Abstract][Full Text] [Related]
33. G protein-coupled receptors as regulators of energy homeostasis.
Tao YX; Yuan ZH; Xie J
Prog Mol Biol Transl Sci; 2013; 114():1-43. PubMed ID: 23317781
[TBL] [Abstract][Full Text] [Related]
34. Physiological relevance of GPCR oligomerization and its impact on drug discovery.
Panetta R; Greenwood MT
Drug Discov Today; 2008 Dec; 13(23-24):1059-66. PubMed ID: 18824244
[TBL] [Abstract][Full Text] [Related]
35. Current status of G-protein coupled receptors as potential targets against type 2 diabetes mellitus.
Hoque M; Ali S; Hoda M
Int J Biol Macromol; 2018 Oct; 118(Pt B):2237-2244. PubMed ID: 30030074
[TBL] [Abstract][Full Text] [Related]
36. Predicting ligands for orphan GPCRs.
Huang ES
Drug Discov Today; 2005 Jan; 10(1):69-73. PubMed ID: 15676301
[TBL] [Abstract][Full Text] [Related]
37. Receptorome screening for CNS drug discovery.
Vortherms TA; Roth BL
IDrugs; 2005 Jun; 8(6):491-6. PubMed ID: 15906196
[TBL] [Abstract][Full Text] [Related]
38. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
[TBL] [Abstract][Full Text] [Related]
39. G protein-coupled receptor dimers: functional consequences, disease states and drug targets.
Dalrymple MB; Pfleger KD; Eidne KA
Pharmacol Ther; 2008 Jun; 118(3):359-71. PubMed ID: 18486226
[TBL] [Abstract][Full Text] [Related]
40. Screening technologies for G protein-coupled receptors: from HTS to uHTS.
De los Frailes M; Diez E
Methods Mol Biol; 2009; 552():15-37. PubMed ID: 19513639
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
